Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Kimberly S. Corbin; William G. Breen; Jonathan B. Strauss

doi:10.1016/j.ctro.2020.06.013

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Kimberly S. Corbin, William G. Breen, Jonathan B. Strauss

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.

Original language	English (US)
Pages (from-to)	99-101
Number of pages	3
Journal	Clinical and Translational Radiation Oncology
Volume	24
DOIs	https://doi.org/10.1016/j.ctro.2020.06.013
State	Published - Sep 2020

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctro.2020.06.013

Cite this

@article{b745a39b9cf24af8abbebb815c73d456,

title = "Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)",

abstract = "Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.",

author = "Corbin, {Kimberly S.} and Breen, {William G.} and Strauss, {Jonathan B.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = sep,

doi = "10.1016/j.ctro.2020.06.013",

language = "English (US)",

volume = "24",

pages = "99--101",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

AU - Corbin, Kimberly S.

AU - Breen, William G.

AU - Strauss, Jonathan B.

PY - 2020/9

Y1 - 2020/9

N2 - Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.

AB - Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.

UR - http://www.scopus.com/inward/record.url?scp=85088019527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088019527&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2020.06.013

DO - 10.1016/j.ctro.2020.06.013

M3 - Article

AN - SCOPUS:85088019527

SN - 2405-6308

VL - 24

SP - 99

EP - 101

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

ER -

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this